| 19/04/2024 |
14:05 to 15:05 |
Golden Hall |
Bladder Module - Metastatic Disease Session |
14:40 to 15:00 |
New checkpoint inhibitor scenarios: combinations, maintenance and sequencing to minimize costs and maximize benefits |
Speaker |
| 19/04/2024 |
14:05 to 15:05 |
Golden Hall |
Bladder Module - Metastatic Disease Session |
15:00 to 15:05 |
Discussion |
Discussant |
| 19/04/2024 |
16:45 to 17:10 |
Golden Hall |
Bladder Module - Metastatic Disease Session |
16:45 to 17:05 |
Erdafitinib in Advanced Urothelial Cancer: Exploring Combinations and Treatment Sequence |
Speaker |
| 19/04/2024 |
16:45 to 17:10 |
Golden Hall |
Bladder Module - Metastatic Disease Session |
17:05 to 17:10 |
Discussion |
Discussant |
| 19/04/2024 |
18:05 to 18:30 |
Golden Hall |
Bladder Module - Metastatic Disease Session |
18:05 to 18:25 |
Toxicity management of enfortumab vedotin and pembrolizumab? Patient cases |
Speaker |
| 19/04/2024 |
18:05 to 18:30 |
Golden Hall |
Bladder Module - Metastatic Disease Session |
18:25 to 18:30 |
Discussion |
Discussant |
